CliffBio
small molecule

OLANZAPINE

OLANZAPINE

Loss of exclusivity—loss of exclusivity
CompanyOMNIVIUM PHARMACEUTICALS LLC

Drug detail

Brand nameOLANZAPINE
Active ingredientOLANZAPINE
Strength10MG/VIAL
Dosage formPOWDER
RouteINTRAMUSCULAR
ModalitySmall molecule
FDA approvalJanuary 2026
Marketing statusRX

More from OMNIVIUM PHARMACEUTICALS LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

OLANZAPINE patent cliff — loss of exclusivity — | CliffBio